WO2021156584A1 - Modulateurs de kv3 - Google Patents

Modulateurs de kv3 Download PDF

Info

Publication number
WO2021156584A1
WO2021156584A1 PCT/GB2020/050268 GB2020050268W WO2021156584A1 WO 2021156584 A1 WO2021156584 A1 WO 2021156584A1 GB 2020050268 W GB2020050268 W GB 2020050268W WO 2021156584 A1 WO2021156584 A1 WO 2021156584A1
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
benzofuran
compound
dione
imidazolidine
Prior art date
Application number
PCT/GB2020/050268
Other languages
English (en)
Inventor
Giuseppe Alvaro
Agostino Marasco
Original Assignee
Autifony Therapeutics Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP20705484.2A priority Critical patent/EP4100402A1/fr
Application filed by Autifony Therapeutics Limited filed Critical Autifony Therapeutics Limited
Priority to KR1020227030594A priority patent/KR20220139923A/ko
Priority to AU2020427632A priority patent/AU2020427632A1/en
Priority to CN202080095972.7A priority patent/CN115066424A/zh
Priority to BR112022013339A priority patent/BR112022013339A2/pt
Priority to MX2022009702A priority patent/MX2022009702A/es
Priority to PCT/GB2020/050268 priority patent/WO2021156584A1/fr
Priority to CA3169057A priority patent/CA3169057A1/fr
Priority to JP2022547757A priority patent/JP2023523501A/ja
Priority to IL295027A priority patent/IL295027A/en
Priority to US17/232,049 priority patent/US20210276985A1/en
Publication of WO2021156584A1 publication Critical patent/WO2021156584A1/fr
Priority to CL2022002081A priority patent/CL2022002081A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

L'invention concerne un composé de formule (I) et des aspects associés.
PCT/GB2020/050268 2018-10-16 2020-02-06 Modulateurs de kv3 WO2021156584A1 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
MX2022009702A MX2022009702A (es) 2020-02-06 2020-02-06 Moduladores de kv3.
KR1020227030594A KR20220139923A (ko) 2020-02-06 2020-02-06 Kv3 조절제
AU2020427632A AU2020427632A1 (en) 2020-02-06 2020-02-06 Kv3 modulators
CN202080095972.7A CN115066424A (zh) 2020-02-06 2020-02-06 Kv3调节剂
BR112022013339A BR112022013339A2 (pt) 2020-02-06 2020-02-06 Moduladores de kv3
EP20705484.2A EP4100402A1 (fr) 2020-02-06 2020-02-06 Modulateurs de kv3
PCT/GB2020/050268 WO2021156584A1 (fr) 2020-02-06 2020-02-06 Modulateurs de kv3
IL295027A IL295027A (en) 2020-02-06 2020-02-06 kv3 modulators
JP2022547757A JP2023523501A (ja) 2020-02-06 2020-02-06 Ｋｖ３モジュレーター
CA3169057A CA3169057A1 (fr) 2020-02-06 2020-02-06 Modulateurs de kv3
US17/232,049 US20210276985A1 (en) 2018-10-16 2021-04-15 Novel compounds
CL2022002081A CL2022002081A1 (es) 2020-02-06 2022-08-02 Moduladores de kv3

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2020/050268 WO2021156584A1 (fr) 2020-02-06 2020-02-06 Modulateurs de kv3

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2019/052937 Continuation-In-Part WO2020079422A1 (fr) 2018-10-16 2019-10-16 Nouveaux composés

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/232,049 Continuation US20210276985A1 (en) 2018-10-16 2021-04-15 Novel compounds

Publications (1)

Publication Number Publication Date
WO2021156584A1 true WO2021156584A1 (fr) 2021-08-12

Family

ID=69591671

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2020/050268 WO2021156584A1 (fr) 2018-10-16 2020-02-06 Modulateurs de kv3

Country Status (11)

Country Link
EP (1) EP4100402A1 (fr)
JP (1) JP2023523501A (fr)
KR (1) KR20220139923A (fr)
CN (1) CN115066424A (fr)
AU (1) AU2020427632A1 (fr)
BR (1) BR112022013339A2 (fr)
CA (1) CA3169057A1 (fr)
CL (1) CL2022002081A1 (fr)
IL (1) IL295027A (fr)
MX (1) MX2022009702A (fr)
WO (1) WO2021156584A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117448440A (zh) * 2023-10-23 2024-01-26 中国人民解放军空军军医大学 Kv3在制备诊断或治疗创伤后应激障碍异常恐惧记忆消退产品中的应用

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011069951A1 (fr) 2009-12-11 2011-06-16 Glaxo Group Limited Dérivés d'imidazolidinedione
WO2012076877A1 (fr) 2010-12-06 2012-06-14 Autifony Therapeutics Limited Dérivés d'hydantoïne utiles en tant qu'inhibiteurs de kv3
WO2012168710A1 (fr) 2011-06-07 2012-12-13 Autifony Therapeutics Limited Dérivés d'hydantoïne en tant qu'inhibiteurs de kv3
WO2013083994A1 (fr) 2011-12-06 2013-06-13 Autifony Therapeutics Limited Dérivés d'hydantoïne utiles comme inhibiteurs de kv3
WO2013175211A1 (fr) 2012-05-22 2013-11-28 Autifony Therapeutics Limited Dérivés d'hydantoïne en tant qu'inhibiteurs de kv3
WO2013175215A1 (fr) 2012-05-22 2013-11-28 Autifony Therapeutics Limited Triazoles en tant qu'inhibiteurs de kv3
WO2013182850A1 (fr) 2012-06-06 2013-12-12 Autifony Therapeutics Limited Modulateurs des canaux potassium kv3 à base de dérivés d'isobenzofuran- 5-yl-oxy(hétéro)aryl-imidazolidine-2,4-dione pour traiter les troubles du snc
WO2013182851A1 (fr) 2012-06-06 2013-12-12 Autifony Therapeutics Limited Prophylaxie ou traitement de maladies dans lesquelles un modulateur des canaux kv3.3 est requis
WO2017098254A1 (fr) 2015-12-10 2017-06-15 Autifony Therapeutics Limited Modulateurs des canaux kv3 pour le traitement de la douleur
WO2017103604A1 (fr) 2015-12-16 2017-06-22 Autifony Therapeutics Limited Hydantoïnes utilisées en tant que modulateurs de canaux kv3
WO2018020263A1 (fr) 2016-07-29 2018-02-01 Autifony Therapeutics Limited Dérivés de cyclobutane utilisés comme modulateurs des canaux potassiques voltage dépendants
WO2018109484A1 (fr) 2016-12-16 2018-06-21 Autifony Therapeutics Limited Modulateurs d'hydantoïne de canaux kv3
WO2019222816A1 (fr) 2018-09-21 2019-11-28 Bionomics Limited Composés substitués par pyridinyle et leurs utilisations
WO2020000065A2 (fr) 2019-03-25 2020-01-02 Bionomics Limited Composés n-hétéroaryle substitués et leurs utilisations
WO2020079422A1 (fr) * 2018-10-16 2020-04-23 Autifony Therapeutics Limited Nouveaux composés

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011069951A1 (fr) 2009-12-11 2011-06-16 Glaxo Group Limited Dérivés d'imidazolidinedione
WO2012076877A1 (fr) 2010-12-06 2012-06-14 Autifony Therapeutics Limited Dérivés d'hydantoïne utiles en tant qu'inhibiteurs de kv3
WO2012168710A1 (fr) 2011-06-07 2012-12-13 Autifony Therapeutics Limited Dérivés d'hydantoïne en tant qu'inhibiteurs de kv3
WO2013083994A1 (fr) 2011-12-06 2013-06-13 Autifony Therapeutics Limited Dérivés d'hydantoïne utiles comme inhibiteurs de kv3
WO2013175211A1 (fr) 2012-05-22 2013-11-28 Autifony Therapeutics Limited Dérivés d'hydantoïne en tant qu'inhibiteurs de kv3
WO2013175215A1 (fr) 2012-05-22 2013-11-28 Autifony Therapeutics Limited Triazoles en tant qu'inhibiteurs de kv3
WO2013182850A1 (fr) 2012-06-06 2013-12-12 Autifony Therapeutics Limited Modulateurs des canaux potassium kv3 à base de dérivés d'isobenzofuran- 5-yl-oxy(hétéro)aryl-imidazolidine-2,4-dione pour traiter les troubles du snc
WO2013182851A1 (fr) 2012-06-06 2013-12-12 Autifony Therapeutics Limited Prophylaxie ou traitement de maladies dans lesquelles un modulateur des canaux kv3.3 est requis
WO2017098254A1 (fr) 2015-12-10 2017-06-15 Autifony Therapeutics Limited Modulateurs des canaux kv3 pour le traitement de la douleur
WO2017103604A1 (fr) 2015-12-16 2017-06-22 Autifony Therapeutics Limited Hydantoïnes utilisées en tant que modulateurs de canaux kv3
WO2018020263A1 (fr) 2016-07-29 2018-02-01 Autifony Therapeutics Limited Dérivés de cyclobutane utilisés comme modulateurs des canaux potassiques voltage dépendants
WO2018109484A1 (fr) 2016-12-16 2018-06-21 Autifony Therapeutics Limited Modulateurs d'hydantoïne de canaux kv3
WO2019222816A1 (fr) 2018-09-21 2019-11-28 Bionomics Limited Composés substitués par pyridinyle et leurs utilisations
WO2020079422A1 (fr) * 2018-10-16 2020-04-23 Autifony Therapeutics Limited Nouveaux composés
WO2020000065A2 (fr) 2019-03-25 2020-01-02 Bionomics Limited Composés n-hétéroaryle substitués et leurs utilisations

Non-Patent Citations (68)

* Cited by examiner, † Cited by third party
Title
"Draft Guidance for Industry Analgesic Indications: Developing Drug and Biological Products", February 2014, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
ANDERSON LA ET AL.: "Increased spontaneous firing rates in auditory midbrain following noise exposure are specifically abolished by a Kv3 channel modulator", HEAR RES., vol. 365, August 2018 (2018-08-01), pages 77 - 89
ARONIADOU-ANDERJASKA V ET AL.: "Mechanisms regulating GABAergic inhibitory transmission in the basolateral amygdala: implications for epilepsy and anxiety disorders", AMINO ACIDS, vol. 32, August 2007 (2007-08-01), pages 305 - 315, XP019519650, DOI: 10.1007/s00726-006-0415-x
BARANAUSKAS GNISTRI A: "Sensitization of pain pathways in the spinal cord: cellular mechanisms", PROG. NEUROBIOL., vol. 54, no. 3, February 1998 (1998-02-01), pages 349 - 65
BARON R ET AL.: "Peripheral input and its importance for central sensitization", ANN. NEUROL., vol. 74, no. 5, November 2013 (2013-11-01), pages 630 - 6
BEN-ARI Y.: "Seizure Beget Seizure: The Quest for GABA as a Key Player", CRIT. REV. NEUROBIOL., vol. 18, no. 1-2, 2006, pages 135 - 144
BENES FM ET AL.: "Circuitry-based gene expression profiles in GABA cells of the trisynaptic pathway in schizophrenics versus bipolars", PNAS, vol. 105, no. 52, December 2008 (2008-12-01), pages 20935 - 20940, XP002519475, DOI: 10.1073/pnas.0810153105
BENNETT DLWOODS CG: "Painful and painless channelopathies", LANCET NEUROL., vol. 13, no. 6, June 2014 (2014-06-01), pages 587 - 99, XP055234985, DOI: 10.1016/S1474-4422(14)70024-9
BERGE S ET AL., PHARMACEUTICAL SALTS. J. PHARM. SCI., vol. 66, 1977, pages 1 - 19
BERGE, BIGHLEYMONKHOUSE, J.PHARM.SCI., vol. 66, 1977, pages 1 - 19
BRAMBILLA P ET AL.: "GABAergic dysfunction in mood disorders", MOL. PSYCH., vol. 8, April 2003 (2003-04-01), pages 721 - 737
BROOKE RE ET AL.: "Association of potassium channel Kv3.4 subunits with pre- and post-synaptic structures in brainstem and spinal cord", NEUROSCIENCE, vol. 126, no. 4, 2004, pages 1001 - 10
BROOKE RE ET AL.: "Immunohistochemical localisation of the voltage gated potassium ion channel subunit Kv3.3 in the rat medulla oblongata and thoracic spinal cord", BRAIN RES., vol. 1070, no. 1, pages 101 - 15, XP025064741, DOI: 10.1016/j.brainres.2005.10.102
BROOKE RE ET AL.: "Spinal cord interneurones labelled transneuronally from the adrenal gland by a GFP-herpes virus construct contain the potassium channel subunit Kv3.1b", AUTON. NEUROSCI., vol. 98, no. 1-2, June 2002 (2002-06-01), pages 45 - 50
CERVERO F.: "Spinal cord hyperexcitability and its role in pain and hyperalgesia", EXP. BRAIN RES., vol. 196, no. 1, June 2009 (2009-06-01), pages 129 - 37, XP019703422
CHAMBERS AR ET AL.: "Pharmacological modulation of Kv3.1 mitigates auditory midbrain temporal processing deficits following auditory nerve damage", SCI REP., vol. 7, no. 1, 13 December 2017 (2017-12-13), pages 17496
CHANG SY ET AL.: "Distribution of Kv3.3 Potassium Channel Subunits in Distinct Neuronal Populations of Mouse Brain", J. COMP. NEURO., vol. 502, February 2007 (2007-02-01), pages 953 - 972
CHIEN LY ET AL.: "Reduced expression of A-type potassium channels in primary sensory neurons induces mechanical hypersensitivity", J. NEUROSCI., vol. 27, no. 37, September 2007 (2007-09-01), pages 9855 - 65
CHOW A ET AL.: "K+ Channel Expression Distinguishes Subpopulations of Parvalbumin- and Somatostatin-Containing Neocortical Interneurons", J. NEUROSCI., vol. 19, no. 21, November 1999 (1999-11-01), pages 9332 - 9345
DESAI R ET AL.: "Protein Kinase C Modulates Inactivation of Kv3.3 Channels", J. BIOL. CHEM., vol. 283, 2008, pages 22283 - 22294
DEUCHARS SA ET AL.: "Properties of interneurones in the intermediolateral cell column of the rat spinal cord: role of the potassium channel subunit Kv3.1", NEUROSCIENCE, vol. 106, no. 2, 2001, pages 433 - 46
DEVULDER J.: "Flupirtine in pain management: pharmacological properties and clinical use", CNS DRUGS, vol. 24, no. 10, October 2010 (2010-10-01), pages 867 - 81
DIB-HAJJ SD ET AL.: "The Na(V)1.7 sodium channel: from molecule to man", NAT. REV. NEUROSCI., vol. 14, no. 1, January 2013 (2013-01-01), pages 49 - 62, XP055127118, DOI: 10.1038/nrn3404
DIOCHOT S ET AL.: "Sea Anemone Peptides with a Specific Blocking Activity against the Fast Inactivating Potassium Channel Kv3.4", J. BIOL. CHEM., vol. 273, no. 12, March 1998 (1998-03-01), pages 6744 - 6749
ENGEL AK ET AL.: "Dynamic Predictions: Oscillations and Synchrony in Top-Down Processing", NAT. REV. NEUROSCI., vol. 2, no. 10, October 2001 (2001-10-01), pages 704 - 716
ESPINOSA F ET AL.: "Ablation of Kv3.1 and Kv3.3 Potassium Channels Disrupts Thalamocortical Oscillations In Vitro and In Vivo", J. NEUROSCI., vol. 28, no. 21, May 2008 (2008-05-01), pages 5570 - 5581
ESPINOSA F ET AL.: "Alcohol Hypersensitivity, Increased Locomotion, and Spontaneous Myoclonus in Mice Lacking the Potassium Channels Kv3.1 and Kv3.3", J. NEUROSCI., vol. 21, no. 17, September 2001 (2001-09-01), pages 6657 - 6665, XP002965922
FIGUEROA K ET AL.: "KCNC3: phenotype, mutations, channel biophysics - a study of 260 familial ataxia patients", HUMAN MUTATION., vol. 31, 2010, pages 191 - 196
FINNERUP NB ET AL.: "Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis", LANCET NEUROL., vol. 14, no. 2, February 2015 (2015-02-01), pages 162 - 73, XP055231928, DOI: 10.1016/S1474-4422(14)70251-0
FISAHN A.: "Kainate receptors and rhythmic activity in neuronal networks: hippocampal gamma oscillations as a tool", J. PHYSIOL., vol. 561, no. 1, October 2005 (2005-10-01), pages 65 - 72
GLAIT L ET AL.: "Effects of AUT00063, a Kv3.1 channel modulator, on noise-induced hyperactivity in the dorsal cochlear nucleus", HEAR RES., vol. 361, April 2018 (2018-04-01), pages 36 - 44, XP085360685, DOI: 10.1016/j.heares.2018.01.017
JOHO RH ET AL.: "Increased γ- and Decreased o-Oscillations in a Mouse Deficient for a Potassium Channel Expressed in Fast-Spiking Interneurons", J. NEUROPHYSIOL., vol. 82, June 1999 (1999-06-01), pages 1855 - 1864, XP002208635
JOHO RHHURLOCK EC: "The Role of Kv3-type Potassium Channels in Cerebellar Physiology and Behavior", CEREBELLUM, vol. 8, February 2009 (2009-02-01), pages 323 - 333
JUNG D ET AL.: "Age-related changes in the distribution of Kv1.1 and Kv3.1 in rat cochlear nuclei", NEUROL. RES., vol. 27, 2005, pages 436 - 440
KACZMAREK L ET AL.: "Regulation of the timing of MNTB neurons by short-term and long-term modulation of potassium channels", HEARING RES., vol. 206, 2005, pages 133 - 145, XP025268330, DOI: 10.1016/j.heares.2004.11.023
KASTEN MR ET AL.: "Differential regulation of action potential firing in adult murine thalamocortical neurons by Kv3.2, Kv1, and SK potassium and N-type calcium channels", J. PHYSIOL., vol. 584, no. 2, 2007, pages 565 - 582
LAU D ET AL.: "Impaired Fast-Spiking, Suppressed Cortical Inhibition, andIncreased Susceptibility to Seizures in Mice Lacking Kv3.2 K+ Channel Proteins", J. NEUROSCI., vol. 20, no. 24, December 2000 (2000-12-01), pages 9071 - 9085
LI W ET AL.: "Localization of Two High-Threshol Potassium Channel Subunits in the Rat Central Auditory System", J. COMP. NEURO., vol. 437, May 2001 (2001-05-01), pages 196 - 218
LU R ET AL.: "Slack channels expressed in sensory neurons control neuropathic pain in mice", J. NEUROSCI., vol. 35, no. 3, January 2015 (2015-01-01), pages 1125 - 35
MARKRAM H ET AL.: "Interneurons of the neocortical inhibitory system", NAT. REV. NEUROSCI., vol. 5, October 2004 (2004-10-01), pages 793 - 807
MARTINA M ET AL.: "Functional and Molecular Differences between Voltage-Gated K+ Channels of Fast-Spiking Interneurons and Pyramidal Neurons of Rat Hippocampus", J. NEUROSCI., vol. 18, no. 20, October 1998 (1998-10-01), pages 8111 - 8125
MCCARBERG BH ET AL.: "The impact of pain on quality of life and the unmet needs of pain management: results from pain sufferers and physicians participating in an Internet survey", AM. J. THER., vol. 15, no. 4, July 2008 (2008-07-01), pages 312 - 20
MCDONALD AJMASCAGNI F: "Differential expression of Kv3.1b and Kv3.2 potassium channel subunits in interneurons of the basolateral amygdala", NEUROSCIENCE, vol. 138, 2006, pages 537 - 547, XP024986568, DOI: 10.1016/j.neuroscience.2005.11.047
MCMAHON A ET AL.: "Allele-dependent changes of olivocerebellar circuit properties in the absence of the voltage-gated potassium channels Kv3.1 and Kv3.3", EUR. J. NEUROSCI., vol. 19, March 2004 (2004-03-01), pages 3317 - 3327
MITCHELL I ET AL.: "Aryl Pyrazoles as Potent Inhibitors of Arginine Methyltransferases: Identification of the First PRMT6 Tool Compound", ACS MED. CHEM. LETT., vol. 6, no. 6, 2015, pages 655 - 659
MUONA M ET AL.: "A recurrent de novo mutation in KCNC1 causes progressive myoclonus epilepsy", NAT GENET., vol. 47, no. 1, January 2015 (2015-01-01), pages 39 - 46
MUQEEM T ET AL.: "Regulation of Nociceptive Glutamatergic Signaling by Presynaptic Kv3.4 Channels in the Rat Spinal Dorsal Horn", J NEUROSCI., vol. 38, no. 15, 11 April 2018 (2018-04-11), pages 3729 - 3740
OLSEN T ET AL.: "Kv3 K+ currents contribute to spike-timing in dorsal cochlear nucleus principal cells", NEUROPHARMACOLOGY, vol. 133, 1 May 2018 (2018-05-01), pages 319 - 333
PILATI N ET AL.: "Acoustic over-exposure triggers burst firing in dorsal cochlear nucleus fusiform cells", HEARING RESEARCH, vol. 283, 2012, pages 98 - 106
PUENTE N ET AL.: "Precise localization of the voltage-gated potassium channel subunits Kv3.1 b and Kv3.3 revealed in the molecular layer of the rat cerebellar cortex by a pre-embedding immunogold method", HISTOCHEM. CELL. BIOL., vol. 134, September 2010 (2010-09-01), pages 403 - 409, XP019848110
REYNOLDS GP ET AL.: "Calcium Binding Protein Markers of GABA Deficits in Schizophrenia - Post Mortem Studies and Animal Models", NEUROTOX. RES., vol. 6, no. 1, February 2004 (2004-02-01), pages 57 - 62
RITTER DM ET AL.: "Dysregulation of Kv3.4 channels in dorsal root ganglia following spinal cord injury", J. NEUROSCI., vol. 35, no. 3, January 2015 (2015-01-01), pages 1260 - 73
RITTER DM ET AL.: "Modulation of Kv3.4 channel N-type inactivation by protein kinase C shapes the action potential in dorsal root ganglion neurons", J. PHYSIOL., vol. 590, January 2012 (2012-01-01), pages 145 - 61
ROBERTS L ET AL.: "Ringing Ears: The Neuroscience of Tinnitus", J. NEUROSCI., vol. 30, no. 45, 2010, pages 14972 - 14979
RUDY BMCBAIN CJ: "Kv3 channels: voltage-gated K+ channels designed for high-frequency repetitive firing", TRENDS IN NEUROSCI., vol. 24, no. 9, September 2001 (2001-09-01), pages 517 - 526, XP004298583, DOI: 10.1016/S0166-2236(00)01892-0
SACCO T ET AL.: "Properties and expression of Kv3 channels in cerebellar Purkinje cells", MOL. CELL. NEUROSCI., vol. 33, July 2006 (2006-07-01), pages 170 - 179, XP024908127, DOI: 10.1016/j.mcn.2006.07.006
SCHULZ PSTEIMER T: "Neurobiology of Circadian Systems", CNS DRUGS, vol. 23, 2009, pages 3 - 13
SONG P ET AL.: "Acoustic environment determines phosphorylation state of the Kv3.1 potassium channel in auditory neurons", NAT. NEUROSCI., vol. 8, no. 10, October 2005 (2005-10-01), pages 1335 - 1342
SPENCER KM ET AL.: "Neural synchrony indexes disordered perception and cognition in schizophrenia", PNAS, vol. 101, no. 49, December 2004 (2004-12-01), pages 17288 - 17293, XP055262529, DOI: 10.1073/pnas.0406074101
SUN S ET AL.: "Inhibitors of voltage-gated sodium channel Nav1.7: patent applications since 2010", PHARM. PAT. ANAL., vol. 3, no. 5, September 2014 (2014-09-01), pages 509 - 21
VON HEHN C ET AL.: "Loss of Kv3.1 Tonotopicity and Alterations in cAMP Response Element-Binding Protein Signaling in Central Auditory Neurons of Hearing Impaired Mice", J. NEUROSCI., vol. 24, 2004, pages 1936 - 1940
WEISER M ET AL.: "Differential Expression of Shaw-related K+ Channels in the Rat Central Nervous System", J. NEUROSCI., vol. 14, no. 3, March 1994 (1994-03-01), pages 949 - 972
WICKENDEN ADMCNAUGHTON-SMITH G: "Kv7 channels as targets for the treatment of pain", CURR. PHARM. DES., vol. 15, no. 15, 2009, pages 1773 - 98
WOOLF CJ.: "What is this thing called pain?", J. CLIN. INVEST., vol. 120, no. 11, November 2010 (2010-11-01), pages 3742 - 4
WOOLF CJ: "Central sensitization: implications for the diagnosis and treatment of pain", PAIN, vol. 152, no. 3, March 2011 (2011-03-01), pages S2 - 15, XP028364045, DOI: 10.1016/j.pain.2010.09.030
YANAGI M ET AL.: "Kv3.1-containing K(+) channels are reduced in untreated schizophrenia and normalized with antipsychotic drugs", MOL PSYCHIATRY, vol. 19, no. 5, 2014, pages 573 - 9
YEUNG SYM ET AL.: "Modulation of Kv3 Subfamily Potassium Currents by the Sea Anemone Toxin BDS: Significance for CNS and Biophysical Studies", J. NEUROSCI., vol. 25, no. 38, March 2005 (2005-03-01), pages 8735 - 8745
ZAMPONI GW ET AL.: "The Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic Potential", PHARMACOL REV., vol. 67, no. 4, October 2015 (2015-10-01), pages 821 - 70, XP055447402, DOI: 10.1124/pr.114.009654

Also Published As

Publication number Publication date
KR20220139923A (ko) 2022-10-17
AU2020427632A1 (en) 2022-08-18
MX2022009702A (es) 2022-09-07
CA3169057A1 (fr) 2021-08-12
CL2022002081A1 (es) 2023-05-26
CN115066424A (zh) 2022-09-16
EP4100402A1 (fr) 2022-12-14
IL295027A (en) 2022-09-01
BR112022013339A2 (pt) 2022-09-13
JP2023523501A (ja) 2023-06-06

Similar Documents

Publication Publication Date Title
US11541052B2 (en) Compounds
US11180461B2 (en) Triazoles as Kv3 inhibitors
US9193704B2 (en) Hydantoin derivatives as KV3 inhibitors
EP3490977B1 (fr) Dérivés cyclobutane comme modulateurs des canaux potassiques voltage-dépendants
EP3390394B1 (fr) Hydantoïnes utilisées en tant que modulateurs de canaux kv3
CA2856654C (fr) Derives d'hydantoine utiles comme inhibiteurs de kv3
WO2020079422A1 (fr) Nouveaux composés
EP3555073A1 (fr) Modulateurs d'hydantoïne de canaux kv3
WO2013182850A1 (fr) Modulateurs des canaux potassium kv3 à base de dérivés d'isobenzofuran- 5-yl-oxy(hétéro)aryl-imidazolidine-2,4-dione pour traiter les troubles du snc
WO2021156584A1 (fr) Modulateurs de kv3
US20210276985A1 (en) Novel compounds
WO2023017263A1 (fr) Modulateurs des canaux potassiques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20705484

Country of ref document: EP

Kind code of ref document: A1

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112022013339

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 3169057

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 3169057

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2022547757

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2020427632

Country of ref document: AU

Date of ref document: 20200206

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20227030594

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 112022013339

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20220704

ENP Entry into the national phase

Ref document number: 2020705484

Country of ref document: EP

Effective date: 20220906